|
11.
|
|
6 p, 332.7 KB |
Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype
/
Páez, David (Institut d'Investigació Biomèdica Sant Pau) ;
Tobeña, María (Institut d'Investigació Biomèdica Sant Pau) ;
Fernández-Plana, Julen (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Virgili, Anna C. (Institut d'Investigació Biomèdica Sant Pau) ;
Cirera, Lluís (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ;
Riera, Pau (Institut d'Investigació Biomèdica Sant Pau) ;
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ;
Salazar, Juliana (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Patients harbouring the UGT1A1 *28/*28 genotype are at risk of severe toxicity with the standard irinotecan dose. However, this dose is considerably lower than the dose that can be tolerated by UGT1A1 *1/*1 and *1/*28 patients. [...]
2018 -  10.1038/s41416-018-0348-7
British Journal of Cancer, Vol. 120 (december 2018) , p. 190-195
|
|
|
12.
|
|
15 p, 1.5 MB |
Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O· production in cancer cells
/
Cordani, Marco (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ;
Butera, Giovanna (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Dando, Ilaria (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Torrens-Mas, Margalida (Institut d'Investigació Sanitària de Palma) ;
Butturini, Elena (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Pacchiana, Raffaella (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Oppici, Elisa (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Cavallini, Chiara (University of Verona. Research Center LURM (Interdepartmental Laboratory of Medical Research)) ;
Gasperini, Sara (Section of General Pathology, University of Verona. Department of Medicine) ;
Tamassia, Nicola (Section of General Pathology, University of Verona. Department of Medicine) ;
Nadal-Serrano, Mercedes (Vall d'Hebron Institut d'Oncologia) ;
Coan, Michela (National Cancer Institute (Aviano, Itàlia)) ;
Rossi, Davide (Institute of Oncology Research) ;
Gaidano, Gianluca (University of Eastern Piedmont. Division of Hematology, Department of Translational Medicine) ;
Caraglia, Michele (Department of Biochemistry, Biophysics and General Pathology, University of Campania "L. Vanvitelli", Naples, Italy) ;
Mariotto, Sofia (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Spizzo, Riccardo (National Cancer Institute (Aviano, Itàlia)) ;
Roca, Pilar (Institut d'Investigació Sanitària de Palma) ;
Oliver, Jordi (Institut d'Investigació Sanitària de Palma) ;
Scupoli, Maria Teresa (University of Verona. Research Center LURM (Interdepartmental Laboratory of Medical Research)) ;
Donadelli, Massimo (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Universitat Autònoma de Barcelona
The TP53 tumor suppressor gene is the most frequently altered gene in tumors and mutant p53 gain-of-function isoforms actively promote cancer malignancy. A panel of wild-type and mutant p53 cancer cell lines of different tissues, including pancreas, breast, skin, and lung were used, as well as chronic lymphocytic leukemia (CLL) patients with different TP53 gene status. [...]
2018 - 10.1038/s41416-018-0288-2
British Journal of Cancer, Vol. 119 (october 2018) , p. 994-1008
|
|
|
13.
|
|
7 p, 1.3 MB |
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
/
Melisi, Davide (University of Verona, Piazzale Ludovico Antonio Scuro) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ;
Pezet, Denis (Centre Hospitalier Universitaire) ;
Deplanque, Gael (Hôpital Riviera-Chablais) ;
Fuchs, Martin (Klinikum Bogenhausen, Städtisches Klinikum München GmbH, Englschalkinger Road 77, 81925 Munich, Germany) ;
Trojan, Jorg (Goethe University Medical Center) ;
Oettle, Helmut (Onkologische und Hämatologische Schwerpunktpraxis, Friedrichshafen, Germany) ;
Kozloff, Mark (Ingalls Memorial Hospital) ;
Cleverly, Ann (Eli Lilly and Company, Erl Wood Manor, Windlesham) ;
Smith, Claire (formerly of Eli Lilly and Company) ;
Estrem, Shawn T. (Eli Lilly and Company, Lilly Corporate Center) ;
Gueorguieva, Ivelina (Eli Lilly and Company, Erl Wood Manor, Windlesham) ;
Lahn, Michael M. F. (Wisconsin Ave., #8008, Bethesda, MD 20815 USA) ;
Blunt, Al (Advaxis, Inc) ;
Benhadji, Karim A. (Eli Lilly and Company) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Universitat Autònoma de Barcelona
Galunisertib is the first-in-class, first-in-human, oral small-molecule type I transforming growth factor-beta receptor (ALK5) serine/threonine kinase inhibitor to enter clinical development. The effect of galunisertib vs. [...]
2018 - 10.1038/s41416-018-0246-z
British Journal of Cancer, Vol. 119 (october 2018) , p. 1208-1214
|
|
|
14.
|
|
7 p, 549.5 KB |
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
/
Powles, Thomas (University of London. Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, Queen Mary) ;
Motzer, Robert J. (Memorial Sloan Kettering Cancer Center) ;
Escudier, Bernard (Gustave Roussy) ;
Pal, Sumanta (City of Hope National Medical Center) ;
Kollmannsberger, Christian (BCCA Vancouver Cancer Centre. British Columbia Cancer Agency) ;
Pikiel, Joanna (Wojewodzkie Centrum Onkologii, 80-219 Gdańsk, Poland) ;
Gurney, Howard (Macquarie University. Macquarie University and Westmead Hospital) ;
Rha, Sun Young (Yonsei Cancer Center. Severance Hospital) ;
Park, Se Hoon (Samsung Medical Center) ;
Geertsen, Poul F. (Copenhagen University Hospital) ;
Gross-Goupil, Marine (Groupe Hospitalier Saint André, 33000 Bordeaux, France) ;
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ;
Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Markby, David W. (Exelixis, Inc) ;
Arroyo, Alan (Exelixis, Inc) ;
Dean, Mark (Exelixis, Inc) ;
Choueiri, Toni K. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
George, Daniel (Duke University Medical Center) ;
Universitat Autònoma de Barcelona
In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy. [...]
2018 - 10.1038/s41416-018-0164-0
British Journal of Cancer, Vol. 119 (september 2018) , p. 663-669
|
|
|
15.
|
|
8 p, 518.2 KB |
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib : comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
/
Solis-Hernandez, Mª Pilar (Hospital Universitario Central de Asturias) ;
Fernandez del Valle, Ana (Hospital Universitario Central de Asturias) ;
Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia)) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
Custodio, Ana (Hospital Universitario La Paz (Madrid)) ;
Benavent, Marta (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Alonso-Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid)) ;
Nuñez-Valdovino, Bárbara (Hospital Clinico Universidad de Chile (Santiago de Xile, Xile)) ;
Sanchez Canovas, Manuel (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Matos, Ignacio (Hospital Universitari Vall d'Hebron) ;
Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa)) ;
Lopez, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Viudez, Antonio (Complejo Hospitalario de Navarra) ;
Izquierdo, Marta (Hospital Universitario Central de Asturias) ;
Calvo-Temprano, David (Hospital Universitario Central de Asturias) ;
Grande, Enrique (MD Anderson Cancer Center) ;
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron) ;
Jimenez-Fonseca, Paula (Hospital Universitario Central de Asturias) ;
Universitat Autònoma de Barcelona ;
Vall d'Hebron Institut d'Oncologia
The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib. A multicentre, prospective study was conducted in 10 Spanish centres. [...]
2019 - 10.1038/s41416-019-0558-7
British Journal of Cancer, Vol. 121 (september 2019) , p. 537-544
|
|
|
16.
|
|
6 p, 374.8 KB |
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
/
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Valladares-Ayerbes, Manuel (Complejo Hospitalario Universitario de A Coruña) ;
Bando, Inmaculada (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Safont, Maria Jose (Hospital General Universitario de Valencia) ;
Gallego, Javier (Hospital General Universitario de Elche) ;
Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ;
Arrivi, Antonio (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Carrato, Alfredo (Hospital Universitario Ramón y Cajal (Madrid)) ;
Conde, Verónica (Hospital Universitario Virgen de las Nieves (Granada)) ;
Ortiz, Maria José (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
López, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Alonso, Beatriz (Hospital Universitario de Canarias (La Laguna)) ;
Ruiz de Mena, Inmaculada (Spanish Cooperative Group for the Treatment of Digestive Tumours) ;
Díaz-Rubio, Eduardo (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Aranda Aguilar, Enrique (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Universitat Autònoma de Barcelona
Targeted agents are standard treatment for RAS wild-type metastatic colorectal cancer in the first- and second-line settings. This phase 2 study determined the benefit of targeting the epidermal growth factor receptor (EGFR) with panitumumab plus irinotecan in irinotecan-refractory patients. [...]
2019 - 10.1038/s41416-019-0537-z
British Journal of Cancer, Vol. 121 (july 2019) , p. 378-383
|
|
|
17.
|
|
10 p, 1.0 MB |
A systematic review and quality assessment of individualised breast cancer risk prediction models
/
Louro, Javier (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ;
Posso, Margarita (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Hilton Boon, Michele (University of Glasgow) ;
Román, Marta (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Domingo, Laia (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Castells, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Sala, Maria (Institut Hospital del Mar d'Investigacions Mèdiques)
Individualised breast cancer risk prediction models may be key for planning risk-based screening approaches. Our aim was to conduct a systematic review and quality assessment of these models addressed to women in the general population. [...]
2019 - 10.1038/s41416-019-0476-8
British Journal of Cancer, Vol. 121 (may 2019) , p. 76-85
|
|
|
18.
|
|
8 p, 6.1 MB |
Poor outcome in hypoxic endometrial carcinoma is related to vascular density
/
Reijnen, Casper (Radboud University Medical Center) ;
van Weelden, Willem Jan (Radboud University Medical Center) ;
Arts, Martijn S. J. P. (Radboud University Medical Center) ;
Peters, Johan P. (Radboud University Medical Center) ;
Rijken, Paul F. (Radboud University Medical Center) ;
van de Vijver, Koen (Universitair Ziekenhuis Gent) ;
Santacana, Maria (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
Bronsert, Peter (Universitätsklinikum Freiburg) ;
Bulten, Johan (Radboud University Medical Center) ;
Hirschfeld, Marc (Universitätsklinikum Freiburg) ;
Colás Ortega, Eva (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gil-Moreno, Antonio 1965- (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Mancebo, Gemma (Hospital del Mar (Barcelona, Catalunya)) ;
Krakstad, Camilla (Haukeland universitetssjukehus) ;
Trovik, Jone (Haukeland universitetssjukehus) ;
Haldorsen, Ingfrid S. (Universitetet i Bergen) ;
Huvila, Jutta (Turun Yliopisto) ;
Koskas, Martin (Hôpital Bichat - Claude-Bernard) ;
Weinberger, Vit (Masarykova univerzita) ;
Minar, Lubos (Masarykova univerzita) ;
Jandakova, Eva (Masarykova univerzita) ;
Snijders, Marc P. L. M. (Canisius Wilhelmina Ziekenhuis) ;
van den Berg-van Erp, Saskia (Canisius Wilhelmina Ziekenhuis) ;
Küsters-Vandevelde, Heidi V. N. (Canisius Wilhelmina Ziekenhuis) ;
Matias-Guiu, Xavier (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
Amant, Frederic (Katholieke Universiteit Leuven) ;
Massuger, Leon F. A. G. (Radboud University Medical Center) ;
Bussink, Johan (Radboud University Medical Center) ;
Pijnenborg, Johanna M. A. (Radboud University Medical Center) ;
Universitat Autònoma de Barcelona
Identification of endometrial carcinoma (EC) patients at high risk of recurrence is lacking. In this study, the prognostic role of hypoxia and angiogenesis was investigated in EC patients. Tumour slides from EC patients were stained by immunofluorescence for carbonic anhydrase IX (CAIX) as hypoxic marker and CD34 for assessment of microvessel density (MVD). [...]
2019 - 10.1038/s41416-019-0461-2
British Journal of Cancer, Vol. 120 (april 2019) , p. 1037-1044
|
|
|
19.
|
|
7 p, 434.6 KB |
SCOT : a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
/
Robles-Zurita, José (University of Glasgow. Institute of Health and Wellbeing) ;
Boyd, Kathleen A. (University of Glasgow. Institute of Health and Wellbeing) ;
Briggs, Andrew H. (University of Glasgow. Institute of Health and Wellbeing) ;
Iveson, Timothy (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Kerr, Rachel S. (University of Oxford. Department of Oncology) ;
Saunders, Mark P. (The Christie Hospital) ;
Cassidy, Jim (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ;
Hollander, Niels Henrik (Zealand University Hospital) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Segelov, Eva (Australasian Gastro-Intestinal Trials Group (AGITG) and Monash University and Monash Health) ;
Glimelius, Bengt (University of Uppsala) ;
Harkin, Andrea (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ;
Allan, Karen (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ;
McQueen, John (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ;
Pearson, Sarah (University of Oxford. Department of Oncology, OCTO) ;
Waterston, Ashita (Beatson West of Scotland Cancer Centre (Glasgow, Regne Unit)) ;
Medley, Louise (Royal United Hospital) ;
Wilson, Charles (Addenbrookes Hospital (Cambridge, Regne Unit)) ;
Ellis, Richard (Royal Cornwall Hospitals NHS Trust) ;
Essapen, Sharadah (St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust) ;
Dhadda, Amandeep S. (Castle Hill Hospital) ;
Hughes, Rob (Mount Vernon Cancer Centre) ;
Falk, Stephen (Bristol Cancer Institute, Bristol, UK) ;
Raouf, Sherif (Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK) ;
Rees, Charlotte (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Olesen, Rene K. (Zealand University Hospital) ;
Propper, David (Barts Cancer Institute (BCI)) ;
Bridgewater, John (University College London) ;
Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust) ;
Farrugia, David (Gloucestershire Oncology Centre, Cheltenham General Hospital) ;
Webb, Andrew (Brighton and Sussex University Hospital Trust) ;
Cunningham, David (Royal Marsden (funded by NIHR BRC at the Royal Marsden)) ;
Hickish, Tamas (Poole Hospital/Bournemouth University) ;
Weaver, Andrew (Churchill Hospital, Oxford University Hospitals Foundation Trust) ;
Gollins, Simon (North Wales Cancer Treatment Centre, Rhyl, UK) ;
Wasan, Harpreet S.. (Hammersmith Hospital (Londres)) ;
Paul, James (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences)
The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer. [...]
2018 - 10.1038/s41416-018-0319-z
British Journal of Cancer, Vol. 119 (november 2018) , p. 1332-1338
|
|
|
20.
|
|
11 p, 1.5 MB |
Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer
/
Dopeso, Higinio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Rodrigues, Paulo (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Bilic Zimmermann, Josipa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Bazzocco, Sarah (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Cartón-Garcia, Fernando (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Macaya, Irati (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
de Marcondes, Priscila Guimarães (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Anguita, Estefanía (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Masanas, Marc (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Jiménez-Flores, Lizbeth M. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martínez-Barriocanal, Águeda (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Nieto Raya, Rocio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Schwartz Jr, Simo (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Mariadason, John M. (La Trobe University School of Cancer Medicine, Olivia Newton-John Cancer Research Institute) ;
Arango, Diego (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
Reduced RHOA signalling has been shown to increase the growth/metastatic potential of colorectal tumours. However, the mechanisms of inactivation of RHOA signalling in colon cancer have not been characterised. [...]
2017 - 10.1038/bjc.2017.420
British Journal of Cancer, Vol. 118 (december 2017) , p. 106-116
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
